CJC-1295 raised growth hormone and IGF-1 for days from a single dose — here is what the studies measured.

Mechanism: a GHRH receptor agonist with an albumin tether

CJC-1295 binds the GHRH receptor, a class B G-protein-coupled receptor on anterior-pituitary somatotrophs. Receptor activation drives the Gs → adenylate cyclase → cAMP → PKA cascade, which promotes GH gene transcription and release; the released GH then acts on hepatic GH receptors via JAK2/STAT5 to produce IGF-1 ^[1][2]. This is the same pathway native GHRH uses — CJC-1295 just resists degradation and, in the DAC form, lingers.

The albumin tether is the design's defining feature. In rats, a series of hGRF(1-29)-albumin bioconjugates was screened; the lead candidate, CJC-1295, combined the four DPP-IV-protective substitutions with covalent bioconjugation to serum albumin and produced a roughly 4-fold increase in GH area-under-the-curve over two hours versus the unconjugated peptide, with the conjugate detectable in plasma beyond 72 hours ^[2]. That rat work is what identified CJC-1295 as a long-lasting GHRH analog in the first place.

What the research reports (GH and IGF-1 effects)

The headline human finding comes from a 2006 study in healthy adults aged 21 to 61. Single subcutaneous doses of 30 or 60 micrograms per kilogram produced dose-dependent increases in mean plasma GH of roughly 2- to 10-fold for 6 days or more, and increases in IGF-1 of 1.5- to 3-fold for 9 to 11 days; after multiple doses, IGF-1 stayed above baseline for up to 28 days ^[1]. From those kinetics the authors estimated a CJC-1295 half-life of 5.8 to 8.1 days.

A companion 2006 study in healthy men aged 20 to 40 sharpened the picture. A single subcutaneous dose of 60 or 90 micrograms per kilogram raised basal GH about 7.5-fold, mean GH by roughly 46%, and IGF-1 by roughly 45% one week later — while the frequency and magnitude of the natural GH pulses were unchanged ^[3]. That preserved pulsatility is a genuinely notable result: continuous GHRH-receptor stimulation did not flatten the body's own pulsatile rhythm.

These are the CJC-1295 benefits as the literature actually documents them — measured changes in GH and IGF-1 in early-phase studies, not demonstrated outcomes in body composition, recovery, or aging. There are no controlled efficacy trials in healthy adults for those endpoints.

Preclinical and proteomic corroboration

In GHRH-knockout mice, 2 micrograms of CJC-1295 given once every 24 hours fully normalized body weight and length, while dosing every 48 to 72 hours was progressively less effective; treatment also raised pituitary GH mRNA ^[4]. The once-daily result confirmed that a long-acting analog can restore GH-axis-dependent growth on an infrequent schedule.

A human proteomic study added orthogonal evidence. In 11 healthy young men, CJC-1295 shifted the serum proteome in reproducible ways — decreasing apolipoprotein A1 and a transthyretin isoform, increasing a C-terminal albumin fragment and immunoglobulin species — and the immunoglobulin/albumin-fragment signal tracked linearly with IGF-1, suggesting candidate biomarkers of GH/IGF-1 axis activation ^[5]. Together with the rat bioconjugate work ^[2], these studies make the receptor-level mechanism one of the better-supported parts of the CJC-1295 record.

CJC-1295 and ipamorelin: the two-receptor rationale

GHRH analogs and growth-hormone-releasing peptides (GHRPs) act through different receptors. CJC-1295 works at the GHRH receptor; ipamorelin works at the ghrelin/GH-secretagogue receptor. Because the two pathways are distinct, combining a GHRH analog with a GHRP can release more GH than either does alone — the standard pharmacological rationale behind the frequently discussed CJC-1295 ipamorelin pairing ^[1].

The rationale is sound; the evidence for the specific combination is not established. There are no controlled human efficacy trials of CJC-1295 with ipamorelin for body-composition or performance outcomes. The synergy is a receptor-biology expectation, and the circulating combination "protocols" are not derived from published trials. This site describes the mechanism, not a regimen.

CJC-1295 among GHRH analogs (sermorelin, tesamorelin)

CJC-1295 belongs to a family of GHRH analogs that includes two approved drugs. Sermorelin is GHRH(1-29) itself; tesamorelin is a stabilized GHRH analog approved for HIV-associated lipodystrophy and is the closest approved-drug comparator to CJC-1295 ^[12]. The structural logic is shared across the class — extend the half-life of a GHRH fragment to sustain GH/IGF-1 stimulation.

The CJC-1295 vs sermorelin question is one readers ask often, and the honest answer is that the literature does not contain a head-to-head trial. What separates CJC-1295 from sermorelin and tesamorelin is approval status and duration of action, not mechanism: sermorelin is a short-acting approved analog, tesamorelin a stabilized approved analog, and CJC-1295 an unapproved one whose DAC variant is engineered for a multi-day half-life ^[1][12]. Direct efficacy comparisons between them are not available, so any "CJC-1295 vs sermorelin" ranking that circulates is an inference, not a measured result. A 2025 Nature Reviews Endocrinology review and a 2024 development review provide the current class-level context for where unapproved analogs like CJC-1295 sit relative to the approved agents ^[12][13].

Reported and theoretical safety concerns

There is no controlled long-term human safety dataset for CJC-1295. The published human exposure is limited to the early pharmacokinetic studies above ^[1][3], so the safety discussion is largely mechanistic and epidemiological rather than trial-based — and the CJC-1295 side effects most often cited follow from sustained GH/IGF-1 elevation.

GH-axis stimulation can cause fluid retention and edema and can affect insulin sensitivity. Sustained IGF-1 elevation raises a theoretical cancer-risk question, since epidemiology links higher circulating IGF-1 to a modestly increased risk of certain cancers ^[9]. Peptide-albumin conjugates can in principle provoke an immune response, and FDA briefing materials for the 2024 Pharmacy Compounding Advisory Committee cited immunogenicity, among other safety concerns, for GH secretagogues including CJC-1295 ^[10].

The original long-acting DAC program is part of this picture. ConjuChem's CJC-1295 (DAC) entered a Phase 2 trial in HIV-associated visceral obesity (NCT00267527); the program was discontinued, and a patient death during the development era is frequently cited in connection with the halted trial — though a causal link to CJC-1295 was not established in the public record ^[7]. The compound's safety profile in healthy adults is, simply, not established.